First patient dosed in the SPaCE-MT trial of MT-302 with CAPOX with or without nivolumab or trastuzumab in 1L advanced gastroesophageal cancer
“In vivo mRNA CARs represent a new class of programmable medicines, and SPaCE‑MT brings this modality into frontline care. The early MT‑302 data demonstrate safety and activity that support combination therapy – expanding options and meaningfully improving outcomes for patients,” said Daniel Getts, Chief Executive Officer of CREATE Medicines.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.